Amyloid imaging, risk disclosure and Alzheimer’s disease: ethical and practical issues

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Hyman BT, Phelps CH, Beach TG et al. National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement.8(1),1–13 (2012).
  MedlineGoogle Scholar
• 2  Knopman DS, Dekosky ST, Cummings JL et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology56(9),1143–1153 (2001).
  Medline CASGoogle Scholar
• 3  Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. J. Neuropathol. Exp. Neurol.71(4),266–273 (2012).
  MedlineGoogle Scholar
• 4  Klunk WE, Engler H, Nordberg A et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann. Neurol.55(3),306–319 (2004).
  Medline CASGoogle Scholar
• 5  Klunk WE, Wang Y, Huang GF et al. The binding of 2-(4´-methylaminophenyl) benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J. Neurosci.23(6),2086–2092 (2003).
  Medline CASGoogle Scholar
• 6  Ikonomovic MD, Klunk WE, Abrahamson EE et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain131(Pt 6),1630–1645 (2008).
  MedlineGoogle Scholar
• 7  Bacskai BJ, Frosch MP, Freeman SH et al. Molecular imaging with Pittsburgh compound B confirmed at autopsy: a case report. Arch. Neurol.64(3),431–434 (2007).
  MedlineGoogle Scholar
• 8  Clark CM, Pontecorvo MJ, Beach TG et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol.11(8),669–678 (2012).
  Medline CASGoogle Scholar
• 9  Cselenyi Z, Jonhagen ME, Forsberg A et al. Clinical validation of ¹⁸F-AZD4694, an amyloid-beta-specific PET radioligand. J. Nucl. Med.53(3),415–424 (2012).
  Medline CASGoogle Scholar
• 10  Vandenberghe R, Van Laere K, Ivanoiu A et al.¹⁸F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a Phase 2 trial. Ann. Neurol.68(3),319–329 (2010).
  MedlineGoogle Scholar
• 11  Rowe CC, Ackerman U, Browne W et al. Imaging of amyloid beta in Alzheimer’s disease with ¹⁸F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol.7(2),129–135 (2008).
  Medline CASGoogle Scholar
• 12  McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement.7(3),263–269 (2011)
  MedlineGoogle Scholar
• 13  Albert MS, Dekosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement.7(3),270–279 (2011).
  MedlineGoogle Scholar
• 14  Dubois B, Feldman HH, Jacova C et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol.9(11),1118–1127 (2010).
  MedlineGoogle Scholar
• 15  Johnson KA, Minoshima S, Bohnen NI et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. J. Nucl. Med.54(3),476–490 (2013).▪▪ Consensus report from leading experts in the field making recommendations regarding appropriate current uses of amyloid imaging in clinical practice.
  Medline CASGoogle Scholar
• 16  Nelson PT, Alafuzoff I, Bigio EH et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropathol. Exp. Neurol.71(5),362–381 (2012).
  MedlineGoogle Scholar
• 17  Kantarci K, Yang C, Schneider JA et al. Antemortem amyloid imaging and beta-amyloid pathology in a case with dementia with Lewy bodies. Neurobiol. Aging33(5),878–885 (2012).
  Medline CASGoogle Scholar
• 18  Lockhart A, Lamb JR, Osredkar T et al. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain130(Pt 10),2607–2615 (2007).
  Medline CASGoogle Scholar
• 19  Fodero-Tavoletti MT, Okamura N, Furumoto S et al.¹⁸F-THK523: a novel in vivo tau imaging ligand for Alzheimer’s disease. Brain134(Pt 4),1089–1100 (2011).
  MedlineGoogle Scholar
• 20  Xia CF, Arteaga J, Chen G et al. [¹⁸F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimers Dement.12,S1552–S5260 (2013).
  Google Scholar
• 21  Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav. Neurol.21(1),117–128 (2009).
  Medline CASGoogle Scholar
• 22  Morris JC, Roe CM, Xiong C et al.APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann. Neurol.67(1),122–131 (2010).
  Medline CASGoogle Scholar
• 23  Rowe CC, Ellis KA, Rimajova M et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging31(8),1275–1283 (2010).
  MedlineGoogle Scholar
• 24  Fleisher AS, Chen K, Liu X et al. Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol. Aging34(1),1–12 (2013).
  Medline CASGoogle Scholar
• 25  Mormino EC, Kluth JT, Madison CM et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain132(Pt 5),1310–1323 (2009).
  Medline CASGoogle Scholar
• 26  Mormino EC, Smiljic A, Hayenga AO et al. Relationships between beta-amyloid and functional connectivity in different components of the default mode network in aging. Cereb. Cortex21(10),2399–2407 (2011).
  MedlineGoogle Scholar
• 27  Pike KE, Savage G, Villemagne VL et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease. Brain130(Pt 11),2837–2844 (2007).
  MedlineGoogle Scholar
• 28  Landau SM, Mintun MA, Joshi AD et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann. Neurol.72(4),578–586 (2012).
  Medline CASGoogle Scholar
• 29  Chetelat G, Villemagne VL, Villain N et al. Accelerated cortical atrophy in cognitively normal elderly with high beta-amyloid deposition. Neurology78(7),477–484 (2012).
  Medline CASGoogle Scholar
• 30  Storandt M, Mintun MA, Head D, Morris JC. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch. Neurol.66(12),1476–1481 (2009).
  MedlineGoogle Scholar
• 31  Doraiswamy PM, Sperling RA, Coleman RE et al. Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology79(16),1636–1644 (2012).
  Medline CASGoogle Scholar
• 32  Sperling RA, Aisen PS, Beckett LA et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement.7(3),280–292 (2011).▪ Set of recommendations from leading experts in the field that proposes defined criteria for preclinical Alzheimer’s disease (AD), and notes the importance of amyloid and other biomarkers within these criteria.
  MedlineGoogle Scholar
• 33  Jack CR Jr, Knopman DS, Jagust WJ et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol.12(2),207–216 (2013).
  Medline CASGoogle Scholar
• 34  Villemagne VL, Burnham S, Bourgeat P et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol.12(4),357–367 (2013).
  Medline CASGoogle Scholar
• 35  Bateman RJ, Xiong C, Benzinger TL et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N. Engl. J. Med.367(9),795–804 (2012).
  Medline CASGoogle Scholar
• 36  Fleisher AS, Chen K, Quiroz YT et al. Florbetapir PET analysis of amyloid-beta deposition in the presenilin 1 E280A autosomal dominant Alzheimer’s disease kindred: a cross-sectional study. Lancet Neurol.11(12),1057–1065 (2012).
  Medline CASGoogle Scholar
• 37  Sperling RA, Karlawish J, Johnson KA. Preclinical Alzheimer disease – the challenges ahead. Nat. Rev. Neurol.9(1),54–58 (2012).
  MedlineGoogle Scholar
• 38  Aisen PS, Vellas B, Hampel H. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer’s disease. Nat. Rev. Drug Discov.12(4),324 (2013).▪ Provides a rationale for the earlier treatment of AD using amyloid-based approaches.
  Medline CASGoogle Scholar
• 39  Reiman EM, Langbaum JB, Fleisher AS et al. Alzheimer’s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J. Alzheimers Dis.26(Suppl. 3),S321–S329 (2011).
  MedlineGoogle Scholar
• 40  Sperling RA, Donohoe M, Aisen PS. The A4 trial: anti-amyloid treatment of asymptomatic Alzheimer’s disease. Alzheimers Dement.8(Suppl. 4),P425–P426 (2012).
  Google Scholar
• 41  Klein EP, Kaye J. Dementia specialists and early adoption of amyloid imaging. J. Alzheimers Dis.33(2),445–450 (2013).
  MedlineGoogle Scholar
• 42  Knopman DS, Jack CR Jr, Wiste HJ et al. Short-term clinical outcomes for stages of NIA–AA preclinical Alzheimer disease. Neurology78(20),1576–1582 (2012).
  Medline CASGoogle Scholar
• 43  Morris JC, Roe CM, Grant EA et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol.66(12),1469–1475 (2009).
  MedlineGoogle Scholar
• 44  Post SG, Whitehouse PJ, Binstock RH et al. The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. JAMA277(10),832–836 (1997).
  Medline CASGoogle Scholar
• 45  Green RC. Risk assessment for Alzheimer’s disease with genetic susceptibility testing: has the moment arrived? Alzheimers Care Q.3,208–214 (2002).
  CASGoogle Scholar
• 46  Goldman JS, Hahn SE, Catania JW et al. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet. Med.13(6),597–605 (2011).▪ Describes and addresses some of the practical and ethical challenges of disclosing predictive genetic test results in AD, many of which would be similar to challenges faced in the disclosure of amyloid imaging results.
  MedlineGoogle Scholar
• 47  Roberts JS. Genetic testing for risk of Alzheimer’s disease: benefit or burden? Neurodegen. Dis. Manage.2(2),141–144 (2012).
  Google Scholar
• 48  Mormino EC, Brandel MG, Madison CM et al. Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage59(2),1152–1160 (2012).
  MedlineGoogle Scholar
• 49  Clark CM, Schneider JA, Bedell BJ et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA305(3),275–283 (2011).
  Medline CASGoogle Scholar
• 50  Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol.10(9),819–828 (2011).
  MedlineGoogle Scholar
• 51  Neumann PJ, Cohen JT, Hammitt JK et al. Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Econ.21(3),238–251 (2012).
  MedlineGoogle Scholar
• 52  Roberts JS, Barber M, Brown TM et al. Who seeks genetic susceptibility testing for Alzheimer’s disease? Findings from a multisite, randomized clinical trial. Genet. Med.6(4),197–203 (2004).
  MedlineGoogle Scholar
• 53  Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Green RC. Genetic risk assessment for adult children of people with Alzheimer’s disease: the Risk Evaluation and Education for Alzheimer’s Disease (REVEAL) study. J. Geriatr. Psychiatry Neurol.18(4),250–255 (2005).
  MedlineGoogle Scholar
• 54  Green RC, Roberts JS, Cupples LA et al. Disclosure of APOE genotype for risk of Alzheimer’s disease. N. Engl. J. Med.361(3),245–254 (2009).
  Medline CASGoogle Scholar
• 55  Shalowitz DI, Miller FG. Disclosing individual results of clinical research: Implications of respect for participants. JAMA294(6),737–740 (2005).
  Medline CASGoogle Scholar
• 56  Lingler JH, Klunk WE. Disclosure of amyloid imaging results to research participants: has the time come? Alzheimers Dement. doi:10.1016/j.jalz.2012.09.014 (2013) (Epub ahead print).▪ Describes ethical and practical issues involved in disclosing amyloid imaging results to research participants, with a focus on those with mild cognitive impairment.
  MedlineGoogle Scholar
• 57  Roberts JS, Christensen KD, Green RC. Using Alzheimer’s disease as a model for genetic risk disclosure: implications for personal genomics. Clin. Genet.80(5),407–414 (2011).
  Medline CASGoogle Scholar
• 58  Korobkin R, Rajkumar R. The Genetic Information Nondiscrimination Act – a half-step toward risk sharing. N. Engl. J. Med.359(4),335–337 (2008).
  Medline CASGoogle Scholar
• 59  Taylor DH Jr, Cook-Deegan RM, Hiraki S, Roberts JS, Blazer DG, Green RC. Genetic testing for Alzheimer’s and long-term care insurance. Health Aff. (Millwood)29(1),102–108 (2010).
  MedlineGoogle Scholar
• 60  Lipkus IM. Numeric, verbal, and visual formats of conveying health risks: suggested best practices and future recommendations. Med. Decis. Making27(5),696–713 (2007).
  MedlineGoogle Scholar
• 61  Gigerenzer G, Edwards A. Simple tools for understanding risks: from innumeracy to insight. BMJ327(7417),741–744 (2003).
  MedlineGoogle Scholar
• 62  Woloshin S, Schwartz LM. How can we help people make sense of medical data? Eff. Clin. Pract.2(4),176–183 (1999).
  Medline CASGoogle Scholar
• 63  Roberts JS, Karlawish JH, Uhlmann WR, Petersen RC, Green RC. Mild cognitive impairment in clinical care: a survey of American Academy of Neurology members. Neurology75(5),425–431 (2010).
  Medline CASGoogle Scholar
• 64  Eckert SL, Katzen H, Roberts JS et al. Recall of disclosed apolipoprotein E genotype and lifetime risk estimate for Alzheimer’s disease: the REVEAL Study. Genet. Med.8(12),746–751 (2006).
  MedlineGoogle Scholar
• 65  Linnenbringer E, Roberts JS, Hiraki S, Cupples LA, Green RC. “I know what you told me, but this is what I think:” perceived risk of Alzheimer disease among individuals who accurately recall their genetics-based risk estimate. Genet. Med.12(4),219–227 (2010).
  MedlineGoogle Scholar
• 66  Klunk WE. Amyloid imaging as a biomarker for cerebral beta-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol. Aging32(Suppl. 1),S20–S36 (2011).▪ Paper from a leading expert in the field summarizing studies that have examined the potential utility of amyloid imaging as a prognostic tool in AD.
  Medline CASGoogle Scholar
• 67  Roberts JS, Tersegno SM. Estimating and disclosing the risk of developing Alzheimer’s disease: challenges, controversies and future directions. Future Neurol.5(4),501–517 (2010).▪▪ Examines challenges involved with different methods of risk assessment for AD, with a focus on ethical and psychosocial issues.
  Google Scholar
• 101  US FDA press release. FDA approves imaging drug Amyvid™. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm299678.htm
  Google Scholar
• 102  European Medicines Agency. Summary of positive opinion on Amyvid [press release] (2012). www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002422/WC500134101.pdf (Accessed 9 April 2013)
  Google Scholar
• 103  Pearson S, Ollendorf D, Colby J; Institute for Clinical and Economic Review Alzheimer’s disease diagnostics policy development group. Diagnostic tests for Alzheimer’s disease: generating and evaluating evidence to inform insurance coverage policy (2012). www.icer-review.org/index.php/Completed-Appraisals/alzheimers.html (Accessed 7 February 2013)▪ Reviews the literature on diagnostic tests for AD, with a strong focus on amyloid imaging; it provides a useful framework for the types of evidence required for such tests to be widely adopted in clinical practice.
  Google Scholar
• 104  Wayne A. Medicare panel says Alzheimer’s brain scans may not help. Bloomberg News (2013). www.businessweek.com/news/2013-2001-30/medicare-panel-says-alzheimer-s-brain-scans-may-not-help (Accessed 7 February 2013)
  Google Scholar
• 105  23AndMe. www.23AndMe.com (Accessed 7 February 2013)
  Google Scholar